Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Days Payable is 134.10 as of Dec. 2025, which is 5% below its 10-year median of 141.04. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Labiana Health ranks better than 67.1% on this metric.
The historical rank and industry rank for Labiana Health's Days Payable or its related term are showing as below:
XMAD:LAB'
s Days Payable Range Over the Past 10 Years
Min: 124.17 Med: 141.04 Max: 152
Current: 124.17
During the past 6 years, Labiana Health's highest Days Payable was 152.00. The lowest was 124.17. And the median was 141.04.
XMAD:LAB's Days Payable is ranked better than 67.1% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs XMAD:LAB: 124.17
Labiana Health's Days Payable
increased
from Dec. 2024 (109.91) to Dec. 2025 (134.10).
It may suggest that Labiana Healthdelayed paying its suppliers.
Labiana Health Days Payable Related Terms
Labiana Health Days Payable Historical Data
* Premium members only.
The historical data trend for Labiana Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Labiana Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Labiana Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Days Payable of 134.10 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Labiana Health and its competitors. This is near median its historical median of 141.04. Over the past decade, Labiana Health's Days Payable has ranged from 124.17 to 152.00. According to the industry distribution chart, Labiana Health ranks #305 out of 927 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is Labiana Health's Days Payable too high?
Labiana Health's current Days Payable of 134.10 is near median its 10-year median of 141.04. Over the past 10 years, this metric has ranged from a low of 124.17 to a high of 152.00. The Drug Manufacturers industry median Days Payable is 90.38. Labiana Health's value of 134.10 is 48.4% above this industry median. Based on the distribution chart, Labiana Health ranks #305 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #305 out of 927 companies for Days Payable. This puts Labiana Health in the upper half of its industry. The industry median Days Payable is 90.38. Labiana Health's value of 134.10 is 48.4% above this benchmark. Historically, Labiana Health's own Days Payable has ranged from 124.17 to 152.00 over the past decade. While the company's 10-year median is 141.04 vs. the industry median of 90.38, Labiana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Days Payable of 134.10 is 48.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Days Payable is 134.10, which is near median its own 10-year median of 141.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Days Payable is 134.10, which is near median its 10-year median of 141.04 and 48.4% above the Drug Manufacturers industry median of 90.38. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Days Payable is 134.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Days Payable: 134.10 (near median its 10-year median of 141.04)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 48.4% above the Drug Manufacturers median (#305 of 927)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
